A team led by investigators at Weill Cornell Medicine and NewYork-Presbyterian has used advanced technology and analytics to map, at single-cell resolution, the cellular landscape of diseased lung tissue in severe COVID-19 and other infectious lung diseases.
Researchers at Weill Cornell Medicine and Cornell University’s Ithaca campus have developed a new computational method for studying genetic and environmental interactions and how they influence disease risk.
Seeking to advance the scope of precision medicine, Weill Cornell Medicine, NewYork-Presbyterian Hospital, and Illumina, Inc. are entering into a collaboration to sequence the complete human genomes of thousands of consenting patients.
Drawing on New York’s diverse population, Weill Cornell Medicine scientists have been awarded grants from the New York Genome Center (NYGC) to study how several types of cancer differ in patients with different genetic backgrounds and point to precision treatments for groups that have been historically underrepresented in cancer research.
Weill Cornell Medicine’s Clinical and Translational Science Center (CTSC) has been awarded a grant from the National Institutes of Health for COVID-19 research.
A new technique that involves growing brain tumors in a miniature laboratory model of the human brain recreated the complex genetics of the disease better than other approaches, according to research by investigators at Weill Cornell Medicine and NewYork-Presbyterian.
Physicians and scientists at Weill Cornell Medicine and NewYork-Presbyterian have rapidly mobilized to confront the COVID-19 pandemic, focusing a broad spectrum of expertise on the critical issues the disease is posing to healthcare workers and public health officials.
The fourth annual NYC Health Hackathon brought together students and faculty members from Weill Cornell Medicine, Cornell’s Ithaca campus and several local and national academic institutions, to develop high-tech healthcare innovations.
A prestigious Cancer Moonshot grant from the National Cancer Institute’s Immuno-Oncology Translational Network will enable investigators to explore the mechanisms that allow slow-growing lung cancer lesions to progress into aggressive malignancies and identify new therapeutic strategies to intercept the transition.
A newly available drug may improve the effectiveness of immunotherapy in hard-to-treat cancers of the upper urinary tract, suggests a study published by Weill Cornell Medicine and NewYork-Presbyterian investigators.
A new artificial intelligence approach by Weill Cornell Medicine investigators can identify with a great degree of accuracy whether a 5-day-old, in vitro fertilized human embryo has a high potential to progress to a successful pregnancy.
Being diagnosed with advanced metastatic pancreatic cancer was a grim experience for Steve Price. But thanks to his doctors at Weill Cornell Medicine and NewYork-Presbyterian, state-of-the-art interventional radiology allowed him to receive chemotherapy immediately after biopsy, shrinking his tumors dramatically.
Weill Cornell Medicine has been awarded a five-year, $9 million Program Project Grant (P01) from the National Cancer Institute (NCI) to better understand how and why patients with an aggressive and incurable form of lymphoma initially respond to treatment, only to relapse over time.
An artificial intelligence program developed by Weill Cornell Medicine and NewYork-Presbyterian researchers can distinguish types of cancer from images of cells with almost 100 percent accuracy, according to a new study.
The complex life cycle of the parasite that causes malaria has made it a difficult foe to beat. But new insights on how the parasite is transmitted from humans to the mosquitoes that spread malaria may lead to new ways to control this deadly disease.
Dr. Olivier Elemento, a renowned computational biologist and leader in the field of computational genomics and biomedicine, has been named director of the Caryl and Israel Englander Institute for Precision Medicine at Weill Cornell Medicine.
